Multiple Myeloma Clinical Trial
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.
The goal of the PROMISE research study is to determine clinical/genomic alterations present in individuals with MGUS and SMM, who are diagnosed though screening of a high-risk population. We also seek to determine clinical/genomic/epigenetic and immune environmental predictors of progression to multiple myeloma in patients with MGUS and SMM.
Age â‰¥ 30 years
AA race (self-identified) and/or first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and WaldenstrÃ¶m's Macroglobulinemia, or another blood cancer.
Those over 18 are also eligible if they have 2 or more family members with a blood cancer
* â€¢ Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic disease requiring active therapy.
â€¢ Persons with an already diagnosed plasma cell dyscrasia such as MGUS, SMM, MM, and WaldenstrÃ¶m's Macroglobulinemia
First-degree relatives would not need to be identified by the participant.
We will include all special populations who fall within the eligible high-risk age range, â‰¥ 30 years of age, including adults unable to consent, pregnant women, and prisoners. These populations will not be excluded as this is a non-therapeutic study.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 3 Locations for this study
Baltimore Maryland, 21287, United States More Info
Rochester Minnesota, 55905, United States More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.